-
Opposition candidate concedes defeat in Benin presidential election
-
SCANDIC COIN, a digital currency within a closed ecosystem
-
'Beautiful' battle with Sinner extra motivation: Alcaraz
-
Szoboszlai says sorry to Liverpool fans after Man City incident
-
Goldman Sachs eyes more corporate mergers despite war uncertainty
-
Star names inspiring Barca teen Yamal for Atletico comeback
-
LVMH sales feel impact from war
-
Satisfaction as Rolling Stones drop track under Cockroaches name
-
Serie A clubs endorse Milan-Cortina chief Malago as football federation president
-
Liverpool need 'very special' night to stun PSG, says Slot
-
Russian, Belarusian swimmers free to compete under own flag
-
Trump vows US will sink any Iran boats that challenge blockade
-
Right-wing candidates tipped for runoff in Peru presidential poll
-
Norwegian effectively cured of HIV after transplant from brother
-
French court gives teacher suspended sentence over pupil's suicide
-
'No warning': Survivors say Nigerian air force bombed packed market
-
Pope says doesn't fear Trump, has 'moral duty to speak out' against war
-
'No fun': French hospital confronts laughing gas abuse
-
Pro-EU Magyar vows 'new era' in Hungary after ousting Orban in vote
-
UK Taylor Swift dance party stabbing spree 'avoidable': inquiry
-
Iran releases assets of football captain in Australia asylum row
-
French court jails Lafarge ex-CEO for funding IS in Syria
-
Atletico need 'personality' to prevent Barca comeback: Koke
-
Cameroon's Catholics divided on papal visit
-
South Africa's new DA leader vows to shed party's white image
-
Karol G honors Latinos in Coachella headline performance: 'Feel proud'
-
Oil surges, stocks drop as Trump threatens to block Hormuz
-
Pope's African tour begins in shadow of Trump ire
-
'Help me!': family's anguish over Equatorial Guinean lured into Ukraine war
-
Germany unveils 1.6 bn euro fuel price relief to tackle energy shock
-
Iran executed at least 1,639 in 2025, more hangings feared: NGOs
-
Ukraine loan, frozen funds: how could Orban's ouster unblock EU?
-
What next for Pogacar, Van der Poel after Roubaix blow?
-
Orban loses Hungary vote to pro-Europe newcomer Magyar
-
US says to begin blockade of Iranian ports
-
Germany to cut fuel taxes amid Iran war energy shock
-
Pope Leo kicks off African tour under shadow of Trump's ire
-
Singer Luisa Sonza shares 'unique experience' of Coachella debut
-
US military to begin blockade of Iranian ports on Monday
-
Australia names Coyle first woman to lead army
-
Rashford with point to prove as Barca target Atletico comeback
-
Iran executed at least 1,639 people in 2025, most since 1989: NGOs
-
Nuggets roll into NBA playoffs, Raptors clinch berth
-
Flagg's sensational rookie season ends with injury
-
Trump says 'not a big fan' of Pope Leo after his anti-war message
-
Spain's Sanchez calls China trade imbalance with EU 'unsustainable'
-
Oil surges, stocks fall as Trump says to blockade Strait of Hormuz
-
Rivers departing as Bucks coach after disappointing season
-
Raptors top Nets, grab No. 5 seed on last day of NBA regular season
-
Greece's ancient sites get climate-change checkup
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
H.Darwish--SF-PST